Alek has a diverse background in drug development spanning more than thirty years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US-based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney-based contract research organisation working with hundreds of clinical stage biotech companies over a twenty-one year period. Alek holds a BPharm and an MBA from the University of Sydney.
Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate startup entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.
Katie has venture capital experience and held roles in Health Economics and Market Access and Account Management at Johnson & Johnson. She holds a BMedSc in Medical Science and an MPhil in Bioscience Enterprise.
Namshik is the Head of Computational Research group at the University of Cambridge Milner Therapeutics Institute. The group develops and applies cutting-edge computational methods, to identify new or better therapies from the analysis of biological data. Prior to Cambridge, he was a postdoc in computational cancer genomics at the University of Manchester. He has also worked in software development for Samsung Electronics.
Jasmin is a Professor of Computational Biology at UCL. The Fisher Lab develops computational tools to study the evolution of cancer and its underlying mechanisms to identify personalised treatment. Prior to joing UCL Jasmin was a Principal Researcher at Microsoft Research in Cambridge and an Associate Professor in Systems Biology at Cambridge University.
Jyoti is head of the Proteomics Core Facility at the Institute of Cancer Research. Her research focuses on the development and implementation of novel mass spectrometry and data analysis approaches for proteome discovery. Prior to joining the ICR, Jyoti was Head of Proteomic Mass Spectrometry at the Wellcome Trust Sanger Institute. She was also a co-founder of Cellzome AG, which was spun out of GSK.